Facebook
X
LinkedIn
Forward
0706_CPMC_Oncology Summit 2025_Live
Description:
This two-day dynamic oncology summit is designed to deliver the latest updates in cancer care, focusing on evidence-based updates in cancer care. This comprehensive program will span key tumor types including melanoma, breast, gynecologic, colorectal, lung, and brain cancers; highlighting cutting-edge research and evolving standards of care. Participants will delve into: Melanoma: Advances in treatment for advanced disease and the latest data on neoadjuvant therapy for resectable nodal melanoma. Gynecologic Oncology: Updates on molecular subtypes and staging in endometrial carcinoma. Breast & Colorectal Cancer: Emerging systemic and targeted therapies, with a focus on personalized approaches. BRAF-Mutant Disease: Shifting paradigms in management and therapeutic strategies. Neurosurgical Oncology: The role of neurosurgery in complex malignancies and multidisciplinary care models. Interactive sessions will foster practical learning, equipping attendees with actionable strategies for patient-centered decision-making in diverse clinical settings.
Assembly Bills 1195 & 241- Culturally Appropriate Care which is Free of Implicit Biases:
Learners are strongly encouraged to engage in self-directed learning related to the impact of implicit biases in this clinical area via the references provided below:
- Jhumkhawala, V., Lobaina, D., Okwaraji, G., Zerrouki, Y., Burgoa, S., Marciniak, A., Densley, S., Rao, M., Diaz, D., Knecht, M., & Sacca, L. (2024). Social determinants of health and health inequities in breast cancer screening: a scoping review. Frontiers in public health, 12, 1354717. https://doi.org/10.3389/fpubh.2024.135471
- Chase, D.M., Salani, R., Farley, J., Torres, T., & Stone, J. (2021, March). Unwittingly biased: A note to gynecologic cancer providers. Gynecologic Oncology, 160(3), 646-648. https://doi.org/10.1016/j.ygyno.2021.01.009
- Helpman, L., Pond, G.R., Elit, L., Anderson, L.N., & Seow, H. (2020, July). Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study. Gynecologic Oncology, 158(1), 130-136. https://doi.org/10.1016/j.ygyno.2020.04.693
- Liang, J., Wolsiefer, K., Zestcott, C.A., Chase, D., & Stone, J. (2019, April). Implicit bias toward cervical cancer: Provider and training differences. Gynecologic oncology, 153(1), 80-86. https://doi.org/10.1016/j.ygyno.2019.01.013
- Maul LV, Ramelyte E, Dummer R, Mangana J. Management of metastatic melanoma with combinations including PD-1 inhibitors. Expert Opin Biol Ther. 2025 May;25(5):1-12. doi: 10.1080/14712598.2025.2485315. Epub 2025 Apr 1. PMID: 40159098.
- Maloney, M.B.E., Bacak, C.B., MSc, K.T.D., Davis, L.M.S., MD, A.B.E., MS, G.A., Cortes, J.M.E., & Miranda-Galvis, M.D.M. (2024, August 2). The intersection of melanoma survival and social determinants of health in the United States: A systematic review. JAAD International, 17, 126-138. https://doi.org/10.1016/j.jdin.2024.07.006
- Michaelson NM, Watsula A, Bakare-Okpala A, Mohamadpour M, Chukwueke UN, Budhu JA. Disparities in Neuro-Oncology. Curr Neurol Neurosci Rep. 2023 Dec;23(12):815-825. doi: 10.1007/s11910-023-01314-x. Epub 2023 Oct 27. PMID: 37889427.
Target Audience
Nurse Practitioner (NP)
Nurse, Registered (RN)
Pharmacists (PharmD)
Physicians (MD or DO)
Physician Assistant (PA)
Other Healthcare Professionals
Learning Objectives
Upon completion of this Summit, participants should be able to:
Presentation Title: Multidisciplinary Management of Metastatic Spine Disease (MSD)
1. Identify team members involved in the management of MSD
2. Identify patients who would benefit from neurosurgery evaluation
3. Describe different treatment modalities used in the management of MSD
Presentation Title: Evolving Standards in the Systemic Management of Breast Cancer
1. Review recent evidence supporting the standard use of systemic therapies in early and late-stage breast cancer
2. Identify novel therapies that may become standard for breast cancer in the next year
Presentation Title: Updates in Endometrial Carcinoma: Integrated Molecular Classification
1. Identify the four molecular subtypes of endometrial carcinoma and understand the prognosis for each.
2. Explain how molecular features are incorporated in staging.
3. Understand the current limitations of implementing new FIGO staging.
Presentation Title: Recent Advances in Systemic Therapy for Melanoma
1. Discuss the latest treatment options for advanced melanoma
2. Summarize the latest data on neoadjuvant therapy for resectable macroscopic nodal melanoma
Presentation Title: Colorectal Cancer: Latest and Greatest
1. Identify treatment options for MSI-H metastatic and localized Colon Cancer
2. List new therapeutic strategies for MSS metastatic Colon Cancer
3. Describe new standard of care for braf mt V600E metastatic Colon Cancer
Presentation Title: Designing a Next-Generation Neuro-Oncology Program: Translating Breakthroughs into Better Care
1. Describe recent advances in molecular diagnostics for neuro-oncology, including next-generation sequencing and circulating tumor DNA, and their role in guiding personalized treatment strategies.
2. Summarize the evolving evidence for targeted therapies in primary and metastatic brain tumors and discuss their integration into clinical practice.
3. Recognize the importance of patient-centered program development in neuro-oncology, emphasizing quality of life, shared decision-making, and multidisciplinary care. Presentation Title: Lung Cancer Updates
1. Identify the magnitude of benefit of the newest therapies for metastatic EGFR, KRAS G12D, ALK, ROS1, HER2 mutant, and c-Met positive NSCLC
2. Recall the efficacy of immunotherapy and targeted therapies in NSCLC in the adjuvant and neoadjuvant setting
3. In advanced small cell lung cancer, identify which line of therapy to use available systemic therapies
Presentation Title: Precision Diagnostics and Next-Generation Surgical Strategies in Prostate Cancer: Integrating Advanced Imaging, Biomarkers, and Robotic Innovations
1. Describe the current approaches to advanced diagnostics in prostate cancer
2. Discuss the state-of-the-art surgical approaches to prostate cancer
Presentation Title: Interventional Pulmonology’s Expanding Role in Lung Cancer Care
1. Describe the evolving role of interventional pulmonology (IP) in lung cancer diagnosis, staging, and treatment.
2. Compare traditional biopsy techniques with advanced modalities such as robotic bronchoscopy and cone-beam CT guidance.
3. Explain the principles and applications of cryobiopsy in lung cancer evaluation.
4. Assess the clinical utility of endobronchial ultrasound (EBUS) for mediastinal staging and lymph node sampling.
5. Discuss emerging therapeutic interventions including pulsed electric field (PEF) ablation and bronchoscopic tumor debulking.
6. Evaluate the integration of IP with molecular diagnostics and personalized oncology.
7. Identify safety profiles and complication rates associated with advanced IP procedures.
8. Review current clinical trials and research directions in interventional pulmonology for lung cancer.
9. Envision future innovations in IP that may transform lung cancer care pathways.
Presentation Title: EUS-Guided Fine Needle Therapy: A Targeted Approach to Pancreatic Neoplasms
1. Summarize the current and emerging roles of endoscopic ultrasound (EUS)-guided therapies in the management of pancreatic cancer.
2. Recognize appropriate clinical scenarios where EUS-guided chemoablation, radiofrequency ablation (RFA), or brachytherapy may serve as alternatives or adjuncts to traditional treatments.
3. Discuss the potential impact of EUS-guided interventions on patient care pathways, including surgical candidacy, local disease control, and integration with systemic therapies.
Sara Hurvitz, MD faculty for this presentation, receives travel support from Novartis and serves as a consultant on the Data Safety Monitoring Boards for Quantum Leap Healthcare and Atossa. These relevant ineligible relationships were mitigated via peer review by Amanda Wheeler, who does not have any ineligible financial relationships.
Akanksha Sharma, MD , faculty for this presentation, holds stock options in Roon, an eligible company and thus no mitigation is required. She also serves as a consultant for Generation Care (Hospice), Servier (Advisory Board), Guidepoint (Survey Research), and Curio Science (Survey Research Panel) and received travel support from MDPI for serving as an Editor for a Special Issue. These relevant ineligible relationships were mitigated via peer review by Amanda Wheeler, who does not have any ineligible financial relationships.
Kevin Kim, MD, faculty for this presentation, holds publicly traded stock in Arvinas, Cryoport, Vertex Pharmaceuticals, and Crispr Therapeutics, and serves as a consultant for Novartis and as a speaker for Bristol Myers Squibb, AstraZeneca, and Daiichi Sankyo. These relevant ineligible relationships were mitigated via peer review by Dr. Natalia Colocci, Dr. Roy Abendroth, Dr. Ian Jaffee, and Dr. Amanda Wheeler who do not have any ineligible financial relationships.
No one else involved in the planning or presentation of this educational activity have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. No financial or in-kind commercial support was received to produce or promote this educational activity.
– Provider Designee/Verification: Fozia Ferozali, Ed.D
In support of improving patient care, Sutter Health, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
Credit Designation Statement
Sutter Health designates this LIVE activity for a maximum of 7.25 AMA PRA Category 1 Credits™ for physicians, 7.25 continuing professional development contact hours for nurses, 7.25 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Note to Other Disciplines: Non-Physician Participation Credit (AKA - AMA PRA Category 1 Credits HOURS™) Continuing Medical Education is acceptable for meeting the continuing education requirements for Pharmacists, Physician Assistants, Psychologists, Registered Nurses, and Respiratory Care Practitioners. For other disciplines, please check with the regulatory board for your discipline to confirm what type of credits meet the continuing education requirements. Continuing education hours for nurses accredited by ANCC, via Joint Accreditation.
Attendance & Credit Claiming
Text the 6-letter attendance verification code to (916) 866-7913 to claim credit.
Available Credit
- 7.25 ACPE
Pharmacy Credit - Accreditation Council of Pharmacy Education (ACPE)
Sutter Health designates this Live activity for a maximum of 7.25 of ACPE credit(s). Credits for pharmacists and technicians will be transmitted to CPE Monitor and will be available within 60 days post-activity pending submission of individual NABP e-PID and DOB (mm/dd only). Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.
- 7.25 AMA PRA Category 1 Credit™
Physician Credit
Sutter Health designates this Live activity for a maximum of 7.25 AMA PRA Category 1 Credit™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 7.25 Non-Physician Participation Credit
Sutter Health designates this Live activity for a maximum of 7.25 Non-Physician Participation Credit. Non-Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMA PRA Category 1 Credits HOURS™ Continuing Medical Education is acceptable for meeting the continuing education requirements for Pharmacists, Physician Assistants, Psychologists, Registered Nurses, and Respiratory Care Practitioners. For other disciplines, please check with the regulatory board for your discipline to confirm what type of credits meet the continuing education requirements. Continuing education hours for nurses accredited by ANCC, via Joint Accreditation.
- 7.25 ANCC
Nursing Credit - American Nurses Credentialing Center (ANCC)
Sutter Health designates this Live activity for a maximum of 7.25 ANCC contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
- 7.25 CA BRN
Nursing Credit - California Board of Registered Nursing (CA BRN)
This activity is approved for 7.25 contact hour(s) by Sutter Health, which is an approved provider by the California Board of Registered Nursing. (Provider Number 17182). Nurses should claim only the credit commensurate with the extent of their participation in the activity. - 7.25 IPCE
This activity was planned by and for the healthcare team, and learners will receive 7.25 Interprofessional Continuing Education (IPCE) credit for learning and change.